Latest Content

Catch up on last week's news in psychiatry.

Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.

Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.

Per capita state suicide prevention funding rose 6-fold from 2021 to 2025 and was more than double in states with 988 telecom fees, study finds.

Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.

New NIH-funded study probes why many callers avoid returning to 988, linking user experiences and state systems to improve crisis support nationwide.

Maurizio Fava, MD, discusses treatment-resistant depression, the placebo response, ketamine research, mentorship, and where AI fits into psychiatry's future.

Phase 3 NEJM data show oveporexton improves wakefulness, reduces cataplexy, and boosts quality of life in narcolepsy type 1, with manageable adverse effects.

How postmodern ideas shape DSM and the biopsychosocial model—why psychiatry needs method-based, truth-seeking care beyond consensus and eclecticism.

Psychedelic psilocybin therapy shows year-long relief in treatment-resistant depression, with strong response rates and stable safety.

Learn why SSRIs impair sex and how bupropion, PDE5 inhibitors, buspirone, and newer agents can prevent or reverse antidepressant sexual side effects.

Catch up on psychiatry news from last week.

FDA boosts DT120 lysergide ODT after phase 3 shows lasting depression relief; psychedelic tablet also advances for anxiety and other brain disorders.